<PAGE>


                     U.S. SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549
                                   FORM 10-QSB

(Mark One)
  X       QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE
-----     ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2000

          TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
------    ACT  OF  1934  FOR  THE   TRANITION   PERIOD  FROM   ____________   TO
          ______________

Commission File Number 2-93277-D



                          MEDIZONE INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)
            Nevada                                    87-0412648
(State or other jurisdiction                (I.R.S. Employer Identification No.)
of incorporation or organization)

                                 144 Buena Vista
                                  P.O. Box 742
                             Stinson Beach, CA 94970
               (Address of principal executive offices, Zip Code)

                                 (415) 868-0300
              (Registrant's telephone number, including area code)

 Check whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports),  and (2) has been
subject to such filing requirements for the past 90 days. Yes [X] No [ ]

At August 1, 2000,  there were  155,615,798  shares of the  registrant's  common
stock issued and outstanding.

Transitional Small Business Disclosure Format
(Check one):
Yes __ No X





<PAGE>


                          MEDIZONE INTERNATIONAL, INC.
                                   FORM 10-QSB
                                      INDEX
                                  June 30, 2000

                                                                          Page
                                                                          Number
Part I - Financial Information

Item 1 - Financial Statements

        Consolidated Balance Sheet:
         -June 30, 2000 and December 31, 1999..................................3

        Consolidated Statement of Operations:
         -For the Three Months and Six Months Ended June 30, 2000 and 1999.....4

        Consolidated Statement of Cash Flow
         -For the Six Months Ended
           June 30, 2000 and 1999..............................................5

             Notes to Consolidated Financial Statements........................6

Item 2 - Management's Discussion and Analysis or Plan of Operation.............7

Part II - Other Information

Item 4 - Submission of Matters to a Vote of Security Holders...................9

Item 6 - Exhibits and Reports on Form 8-K ....................................10




                                       2

<PAGE>


                   MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                      CONDENSED CONSOLIDATED BALANCE SHEET
                       June 30, 2000 and December 31, 1999


<TABLE>
<CAPTION>
                                                           ASSETS

                                                                       June 30,            December 31,
                                                                         2000                  1999
                                                                  -------------------   -------------------
CURRENT ASSETS                                                       (Unaudited)
<S>                                                               <C>                   <C>
    Cash and cash equivalents                                     $           72,037    $            4,388
                                                                  -------------------   -------------------
        Total Current Assets                                                  72,037                 4,388
                                                                  -------------------   -------------------

PROPERTY AND EQUIPMENT, net                                                   18,168                 5,667
                                                                  -------------------   -------------------


                                                                  $           90,205    $           10,055
                                                                  ===================   ===================
</TABLE>
<TABLE>
<CAPTION>

                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES
<S>                                                               <C>                   <C>
    Accounts payable                                              $         235,037     $          395,370
    Accrued expenses                                                         322,265               527,045
    Current portion of long-term obligations                                 280,491               280,491
                                                                  -------------------   -------------------
        Total Current Liabilities                                            837,793             1,202,906
                                                                  -------------------   -------------------

STOCKHOLDERS' EQUITY (DEFICIT)
    Common stock                                                             155,616               149,888
    Additional paid-in capital                                            13,163,754            12,676,882
    Deficit accumulated during the development stage                     (14,066,958)          (14,019,621)
                                                                  -------------------   -------------------
        Total Stockholders' Equity (Deficit)                                (747,588)           (1,192,851)
                                                                  -------------------   -------------------

                                                                  $           90,205    $           10,055
                                                                  ===================   ===================
</TABLE>






                             See accompanying notes.

                                       3

<PAGE>


                   MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                 CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS


<TABLE>
<CAPTION>
                                                       Three        Three         Six           Six
                                                      Months       Months        Months       Months
                                                       Ended        Ended        Ended         Ended
                                                      6/30/00      6/30/99      6/30/00       6/30/99
                                                    ------------ ------------ ------------- ------------

<S>                                                 <C>          <C>          <C>           <C>
           REVENUE                                  $         -  $         -  $          -  $         -
           COST OF SALES                                      -            -             -            -
                                                    ------------ ------------ ------------- ------------
             Gross Profit                                     -            -             -            -
                                                    ------------ ------------ ------------- ------------

           COSTS AND EXPENSES
             Research and development                    25,765            -        80,808            -
             Depreciation and amortization                1,595            -         2,431            -
             General and administrative                 212,049       13,857       367,878       41,338
                                                    ------------ ------------ ------------- ------------
                Total Costs and Expenses                239,409       13,857       451,117       41,338
                                                    ------------ ------------ ------------- ------------

           LOSS BEFORE OTHER INCOME (EXPENSE)          (239,409)     (13,857)     (451,117)     (41,338)
                                                    ------------ ------------ ------------- ------------

           OTHER INCOME (EXPENSE)
             Restitution proceeds                             -            -       415,000            -
             Interest expense                            (5,610)      (5,610)      (11,220)     (11,220)
             Interest income                                  -            -             -            -
                                                    ------------ ------------ ------------- ------------
                Total Other Income (Expense) - net       (5,610)      (5,610)      403,780      (11,220)
                                                    ------------ ------------ ------------- ------------

           LOSS BEFORE INCOME TAXES                    (245,019)     (19,467)      (47,337)     (52,558)

           INCOME TAX BENEFIT (PROVISION)                     -            -             -            -
                                                    ------------ ------------ ------------- ------------

           NET INCOME (LOSS)                        $  (245,019) $   (19,467) $    (47,337) $   (52,558)
                                                    ============ ============ ============= ============

           NET INCOME (LOSS) PER COMMON
             SHARE
             Basic                                  $     (0.00) $     (0.00) $      (0.00) $     (0.00)
                                                    ============ ============ ============= ============

             Diluted                                $     (0.00) $     (0.00) $      (0.00) $     (0.00)
                                                    ============ ============ ============= ============

           AVERAGE COMMON AND EQUIVALENT
             SHARES
             Basic                                  155,615,798  149,148,656   155,479,131  149,111,619
                                                    ============ ============ ============= ============

             Diluted                                155,615,798  149,148,656   155,479,131  149,111,619
                                                    ============ ============ ============= ============

</TABLE>


                                       4




                             See accompanying notes.


<PAGE>


                   MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARY
                          (A Development Stage Company)
                 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
                 For the Six months Ended June 30, 2000 and 1999


<TABLE>
<CAPTION>
                                                                        June 30,            June 30,
                                                                          2000                1999
                                                                    -----------------   ------------------
CASH FLOWS FROM OPERATING ACTIVITIES
<S>                                                                 <C>                 <C>
     Net income (loss)                                              $        (47,337)   $         (52,558)
     Adjustments to reconcile net income (loss) to net
             cash provided by operating activities
         Depreciation and amortization                                         2,431                  972
         Issuance of stock for services                                      272,600                    -
         Interest expense                                                     11,219                    -
     Change in operating assets and liablilites
         Accounts payable and other liabilities                             (376,333)              28,481
                                                                    -----------------   ------------------
                                                                            (137,420)             (23,105)
                                                                    -----------------   ------------------

CASH FROM INVESTING ACTIVITIES
     Acquisition of property and equipment                                   (14,931)                   -
                                                                    -----------------   ------------------
                                                                             (14,931)                   -
                                                                    -----------------   ------------------

CASH FROM FINANCING ACTIVITIES
     Proceeds from issuance of common stock                                  220,000               15,556
                                                                    -----------------   ------------------
                                                                             220,000               15,556
                                                                    -----------------   ------------------

NET CHANGE IN CASH AND CASH EQUIVALENTS                                       67,649               (7,549)

CASH AND CASH EQUIVALENTS
     Beginning of period                                                       4,388                7,643
                                                                    -----------------   ------------------
     End of period                                                  $         72,037    $              94
                                                                    =================   ==================

SUPPLEMENTAL CASH FLOW INFORMATION Cash paid during the period for:
         Interest                                                   $              -    $               -
                                                                    =================   ==================
         Income taxes                                               $              -    $               -
                                                                    =================   ==================

NON-CASH INVESTING AND FINANCING
     ACTIVITIES
     Issuance of common stock for services                          $        272,600    $               -
                                                                    =================   ==================
</TABLE>






                             See accompanying notes.


                                       5

<PAGE>


                   MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARY
                          (A Development Stage Company)
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1 - Basis of Presentation

     The  financial  information  included  herein  is  unaudited  and has  been
prepared  consistent with generally accepted  accounting  principles for interim
financial  information and with the  instructions to Form 10-QSB and Item 310(b)
of Regulation S-B.  Accordingly,  these financial  statements do not include all
information and footnotes required by generally accepted  accounting  principles
for  complete  financial   statements.   These  statements  should  be  read  in
conjunction with the audited financial  statements and notes thereto included in
the Company's  annual report on Form 10-K for the year ended  December 31, 1999.
In the opinion of management, these financial statements contain all adjustments
(consisting solely of normal recurring adjustments) which are, in the opinion of
management,  necessary  for a fair  statement of results for the interim  period
presented.

     The results of  operations  for the six months ended June 30, 2000 and 1999
are not necessarily indicative of the results to be expected for the full year.

2 - Income (Loss) Per Share

     Following is a  reconciliation  of the  numerators of the basic and diluted
income (loss) per share for the six months ended June 30, 2000 and 1999:

<TABLE>
<CAPTION>
                                             Three         Three         Six          Six
                                             Months       Months       Months        Months
                                             Ended         Ended        Ended        Ended
                                            6/30/00       6/30/99      6/30/00      6/30/99
                                          ------------- ------------ ------------ -------------
<S>                                       <C>           <C>          <C>          <C>
Net  income (loss) available to common
    shareholders                          $   (245,019) $   (19,467) $   (47,337) $    (52,558)
                                          ============= ============ ============ =============

Weighted average shares                    155,615,798  149,148,656  155,479,131   149,111,619
Effect of dilutive securities                        -            -            -             -
                                          ------------- ------------ ------------ -------------

                                           155,615,798  149,148,656  155,479,131   149,111,619
                                          ============= ============ ============ =============

Basic income (loss) per share (based on
    weighted average shares)              $      (0.00) $     (0.00) $     (0.00) $      (0.00)
                                          ============= ============ ============ =============

Diluted income (loss) per share           $      (0.00) $     (0.00) $     (0.00) $      (0.00)
                                          ============= ============ ============ =============
</TABLE>


3 - Capital Stock

During the  quarter  ended June 30,  2000,  no common  shares were issued by the
Company.

                                       6

<PAGE>


Item 2 - Management's Discussion and Analysis or Plan of Operation

     The following  discussion and analysis of the Company's financial condition
and  results of  operations  should be read in  conjunction  with the  unaudited
Consolidated  Financial Statements and Notes thereto appearing elsewhere in this
Quarterly Report on Form 10-QSB.

     The Company is a development  stage company,  primarily engaged in research
and development of ozone based treatment for diseases and health problems caused
by lipid enveloped viruses,  including, for example,  Acquired Immune Deficiency
Syndrome (AIDS),  Hepatitis B, Hepatitis C and Herpes, and in the development of
technology for the  decontamination  of blood,  blood products and  veterinarian
serum  products.  The  Company is also  pursuing  the  development  of  external
applications of its technology for medical purposes.

     The  Company  has not  generated,  and  cannot  predict  when or if it will
generate,  significant  revenues or sufficient  cash flow to fund its continuing
operations.  It has funded its operations to date primarily  through the sale of
its  securities.  The  technology and its uses are subject to regulations of the
U.S.  Food and Drug  Administration  ("FDA")  and its  counterparts  in  foreign
countries.  The  Company  does not  intend to sell  equipment  or  supplies  for
ozone-generating purposes until it receives required government approvals.

     Testing  and  trials  can be  conducted  on a limited  basis  for  research
purposes and to establish  efficacy of machines  and  applications,  in order to
support applications for government approvals.  In November of 1997, Dr. Sunnen,
the Director of Research  (who later was  appointed  president of the Company on
April  15,  1998) was  instrumental  in  establishing  a  protocol  for Phase II
research to be performed at several leading Italian university research facility
under the auspices of the European Union. It has now been  determined,  based on
information  regarding the low toxicity levels demonstrated in earlier research,
that European Union health  authorities will accept  completion of a small-scale
Phase I clinical  study with 8-10 patients prior to starting the Phase II trial.
The Company is currently  preparing  submission  papers for a study  designed to
meet these criteria.

     The Company also has recently  conducted trial  treatment  studies on eight
patients  infected  with  Hepatitis  C. This  study was  conducted  through  the
guidance  of Dr.  William  Hitt,  a  former  member  of the  Company's  board of
directors.  The tests  indicated  significant  reductions  in  enzyme  levels as
measured by SGOT and SGPT standard test procedures of the patients participating
in the study.  Enrollment  has begun for a new study of Hepatitis  C,  involving
10-12  patients,  with clinical data analyzed by an independent  facility in Los
Angeles,  California.  Testing will be conducted  prior to, during and following
the completion of treatment and a six-week convalescence follow-up.

     In March 2000, the Company received notification that it had been granted a
patent by the US Patent and  Trademark  Office on its  application  for a patent
covering the external  applications  of ozone for medical  purposes.  The patent
application,  no.  09/126,504,  had been filed on July 30, 1998.  Problems  that
might be  addressed  by such uses  would  include  treatment  of  severe  burns,
infections  of  ulcerations  of the skin  (such as those that might be caused by
advanced  stages of diabetes) or other wounds.  In  connection  with this use of
ozone, the Company has been granted US Patent No. 9/126504,  titled External Use
of  Ozone/Oxygen  for  Pathogenic  Conditions.  Foreign  applications  are being
processed.

     In May 2000, the Company filed another  patent  application  no.  1299-4015
under the title "Method and Apparatus  for Ozone  Decontamination  of Biological
Liquids.

     In addition,  the Company owns patents  covering its ozone  decontamination
technology filed in the United States (no. 4,632,980,  December 30, 1986 and no.
5,052,382,  October 1, 1991),  and related  patents  granted in several  foreign
countries. These patents form the basis for the Company's technology used in the
studies described above.

     The  Company  has  also  been   active  in   pursuing   veterinary   trials
investigating  the  effectiveness  of ozone in  deactivation of viruses in serum
products.  The Phase I trial on healthy serum  products was concluded in October
1999 and was deemed successful by the Company's researchers.  Dr. Sunnen expects
that a Phase II trial  should  also be  successful  based on the  results of the
first round.  The Phase II trial commenced in November and will  investigate the
deactivation rates of seven different viruses and is expected to be completed in
12 to 18 months.  If the results are  satisfactory,  the  Company  believes  its
technology  can be used in the  veterinary  medicine field to form the basis for
the creation of a line of safer and more effective vaccines.


                                       7

<PAGE>

         There is no  assurance  that the results of such tests and studies will
be favorable to the Company or that  regulatory  approval will be received based
on such results.

Results of Operations

General

     From its inception (January 1986), the Company has been a development stage
company  primarily  engaged in  research  into the  medical  uses of ozone.  The
Company  has not  generated,  and cannot  predict  when or if it will  generate,
revenues or sufficient cash flow to fund its continuing operations.

Three  Months  Ended June 30, 2000  compared to the Three  Months Ended June 30,
1999:

     There were no sales  during the quarters  ended June 30, 2000 or 1999.  The
Company made  expenditures for research and development of $25,765 in the second
quarter  of  2000  and  none  in  the  second  quarter  of  1999.   General  and
administrative  expenses in the second quarter of 2000 were $212,049 compared to
$13,857 during the second quarter of 1999. These expenses  include  professional
fees, payroll, insurance costs and travel expenses.

     Interest  expense  accrued  during the three months ended June 30, 2000 was
$5,610, compared to $5,610 in the three months ended June 30, 1999.

Six Months Ended June 30, 2000 compared to the Six Months Ended June 30, 1999:

     There were no sales during the six months ended June 30, 2000 or 1999. Cash
of  $415,000  was  provided  in the  first  quarter  of 2000 by the  receipt  of
restitution  payments  from a former  officer and  director.  The  Company  made
expenditures  for  research and  development  of $80,808 in the six months ended
June 30,  2000 and none in the six  months  ended  June 30,  1999.  General  and
administrative  expenses  in the six months  ended June 30,  2000 were  $367,878
compared to $41,338  during the six months ended June 30, 1999.  These  expenses
include professional fees, payroll, insurance costs and travel expenses.

     Interest  expense  accrued  during the six months  ended June 30,  2000 was
$11,220, compared to $11,220 in the six months ended June 30, 1999.

Liquidity and Capital Resources

     At June 30, 2000, the Company had a working capital  deficiency of $765,756
and stockholders'  deficiency of $747,588. At December 31, 1999, the Company had
a working  capital  deficiency of $1,1198,518  and  stockholders'  deficiency of
$1,192,851.

     Net cash used in operating activities was $137,420 for the six months ended
June 30,  2000.  During the six months  ended June 30,  1999,  the Company  used
$23,105 in operating activities.  Cash of $415,000 was provided in the first six
months of 2000 by the receipt of restitution  payments from a former officer and
director  and  $220,000  was  provided by the sale of the  Company's  securities
through the exercise of outstanding stock purchase warrants.

     During the six months  ended June 30,  2000,  the Company  issued stock and
paid cash to settle  outstanding  liabilities.  These  transactions  include the
following:

     Payment  of  $27,500 to former  legal  counsel of the  Company to retire an
outstanding obligation totaling $69,392;

     Payment of $15,000  and  issuance of 20,000  shares of common  stock of the
Company to settle an obligation  totaling  $39,824 to a former legal counsel for
the Company; and

     Payment of $40,000 and  issuance of 100,000  shares of common  stock to the
Company's patent counsel to settle an outstanding bill of $102,000.

                                       8

<PAGE>


     The Company  will  continue to require  additional  funding to enable it to
fund  research  necessary to make the  appropriate  regulatory  application  and
continue  operations.  It is  expected  that these funds will be provided by the
sale of the Company's securities.

     The Company has  developed a strategy,  which it believes will enable it to
fund  requisite  research  necessary to gain  regulatory  approvals and continue
operations. This strategy depends upon the sale of the Company's common stock or
other  securities  to  certain  accredited  investors.   The  Company  has  also
structured and recently  implemented a cohesive  scientific plan  encompassing a
number of research initiatives,  which it believes may enable it to successfully
achieve its primary  goals.  Those goals include the  submission of  appropriate
research  data to the FDA Center for Drugs and Biologics for the approval of its
blood decontamination process and to the FDA Division of Antiviral Drug Products
for approval of Phase I human  clinical  trial status for the  treatment of AIDS
and Hepatitis. There can be no assurance that either the funding strategy or the
scientific plan will be successful.  Failure to obtain  requisite  funding would
have a materially adverse effect on the Company and its financial condition.

     The Company  recognizes that, if it is unable to raise additional  capital,
it may find it necessary to substantially reduce, or cease operations.

Forward-Looking Statements and Risks Affecting the Company

     The statements  contained in this Report on Form 10-QSB that are not purely
historical are  "forward-looking  statements"  within the meaning of the Private
Securities  Litigation  Reform  Act of 1995 and  Section  21E of the  Securities
Exchange  Act.  These  statements  regard  the  Company's  expectations,  hopes,
beliefs,  anticipations,  commitments,  intentions and strategies  regarding the
future.  They  may be  identified  by the  use  of  words  or  phrases  such  as
"believes,"  "expects,"   "anticipates,"  "should,"  "plans,"  "estimates,"  and
"potential,"  among  others.  Forward-looking  statements  include,  but are not
limited to,  statements  contained in  Management's  Discussion  and Analysis of
Financial Condition and Results of Operations  regarding the Company's financial
performance, revenue and expense levels in the future and the sufficiency of its
existing assets to fund future  operations and capital  spending  needs.  Actual
results  could  differ   materially  from  the  anticipated   results  or  other
expectations  expressed  in such  forward-looking  statements  for  the  reasons
detailed in the Company's Annual Report on Form 10-K for the year ended December
31, 1999 under the headings  "Description  of Business" and "Risk  Factors." The
fact that some of the risk  factors may be the same or similar to the  Company's
past reports filed with the Securities and Exchange  Commission  means only that
the risks are present in multiple periods. The Company believes that many of the
risks  detailed here and in the Company's SEC filings are part of doing business
in the  industry in which the Company  operates  and competes and will likely be
present in all periods reported.  The fact that certain risks are endemic to the
industry  does not lessen their  significance.  The  forward-looking  statements
contained  in this report are made as of the date of this Report and the Company
assumes no obligation to update them or to update the reasons why actual results
could differ from those  projected  in such  forward-looking  statements.  Among
others,  risks  and  uncertainties  that  may  affect  the  business,  financial
condition,  performance,  development,  and results of operations of the Company
include:

     o    rigorous  government  scrutiny  and  regulation  of the  products  and
          planned products of the Company;

     o    potential  effects of adverse  publicity  regarding  ozone and related
          technologies or industries;

     o    failure  of the  Company to sustain  or manage  growth  including  the
          failure to continue to develop new products; and

     o    the ability of the Company to obtain needed financing.

Part II - Other Information

Item 4 - Submission of Matters to a Vote of Security Holders

     The Annual Meeting of Shareholders of the Company was held at the Spinnaker
Restaurant,  100 Spinnaker Dr.,  Sausalito,  California,  on Wednesday,  May 31,
2000. The following business was conducted at the meeting:

     1.   Election of Edwin G.  Marshall,  Gerard V. Sunnen and Richard  Garrett
          Solomon, as directors of the Company, and

                                       9

<PAGE>


     2.   Ratification  of the  selection  of HJ &  Associates  (formerly  Jones
          Jensen & Co.) as the Company's independent public accountants.

Voting results were as follows:

                               For                 Against          Abstain
Proposal 1 (Directors):
  Mr. Marshall                 92,520,651          150,150          850,692
  Mr. Sunnen                   92,520,651          150,150          850,692
  Mr.  Solomon                 92,520,651          150,150          850,692

                               For                 Against          Abstain
Proposal 2 (Auditors)          92,250,651          150,150          850,692

Item 5 - Other Information

     During the quarter  ended June 30, 2000,  Dr.  William  Hitt  resigned as a
member of the Board of Directors  of the Company  citing  health  concerns and a
desire to ease his professional  workload. Dr. Hitt will continue to operate his
William  Hitt  Clinic  and  intends  to  continue  to use  the  Company's  ozone
generating  equipment  to further  the  Company's  research  and  clinical  data
gathering efforts. At the same meeting,  Richard Solomon was elected to serve on
the Board.

Item 6 - Exhibits and Reports on Form 8-K

         (a)      Exhibits

                  Exhibit No.               Description

                  27                        Financial Data Schedule


                                       10

<PAGE>


                                   SIGNATURES


         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                                 MEDIZONE INTERNATIONAL, INC.
                                 (Registrant)


                                 /s/ Edwin G. Marshall
                                 Edwin G. Marshall, Chairman and Chief Executive
                                 Officer (Principal Executive Officer)

                                 /s/ Kevin R. Andersen
                                 Kevin R. Andersen, Chief Financial Officer
                                 (Principal Accounting Officer)



August 4, 2000